.jpeg)
2026-05-29 07:46:00
A comprehensive analysis of the latest clinical data for the highly selective KRAS G12C inhibitor Garsorasib in NSCLC and solid tumors, covering first-line chemotherapy combinations, immunotherapy regimens, brain metastasis efficacy, and resistance management.
2026-05-29 07:43:00
An in-depth analysis of the core differences between Risankizumab (p19 inhibitor) and Ustekinumab (p40 inhibitor) in target mechanisms, efficacy in psoriasis and Crohn's disease, dosing frequency, and safety profiles.
2026-05-29 07:39:18
A comprehensive guide on the dosing, administration, and adverse effect management of Tafasitamab combined with Lenalidomide for relapsed or refractory DLBCL.
2026-05-28 02:37:56
Pirtobrutinib (brand name Jaypirca) is the world's first approved non-covalent (reversible) BTK inhibitor, specifically designed to overcome resistance to traditional covalent BTK inhibitors. This article details its clinical application, dosage management, and safety monitoring strategies in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
2026-05-28 02:19:21
Resmetirom (brand name Rezdiffra) is the world's first approved targeted therapy for metabolic dysfunction-associated steatohepatitis (MASH/NASH). This article highlights three critical safety considerations for patients and healthcare professionals to optimize treatment outcomes.
2026-05-28 02:09:41
covering pre-test preparation, midnight dosing, blood sampling, and result interpretation.
2026-05-28 01:55:16
Gilteritinib is a targeted therapy designed for specific genetic mutations.To ensure safety and efficacy,patients must take this medication under the strict supervision of a hematologist or oncologist.Close follow-up and individualized management are essential.In the event of severe adverse reactions,treatment interruption or dose adjustments may be required.
2026-05-27 06:26:35
Pirtobrutinib (Brand Name: Jaypirca) is a next-generation reversible BTK inhibitor offering a new lifeline for patients with relapsed or refractory Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL/SLL). This article details its mechanism against BTK resistance, clinical efficacy, and safety profile.
2026-05-27 05:45:14
Revumenib, a first-in-class oral Menin-MLL1 inhibitor, offers a targeted therapeutic option for acute leukemia patients with KMT2A rearrangements or NPM1 mutations. This article outlines its mechanism of action, management of Differentiation Syndrome, cardiac monitoring protocols, and long-term follow-up strategies for global clinical practice.
2026-05-27 02:05:59
Zongertinib (Hernexeos) gains FDA approval for HER2-mutated NSCLC, offering targeted therapy based on 76% response rate data, transforming treatment landscape.
2026-05-26 04:51:38
A comprehensive analysis of the synergistic mechanisms, global clinical research, safety management, and application of the Ixazomib and Pomalidomide combination for relapsed/refractory multiple myeloma.
2026-05-25 04:22:45
Discover how Etrasimod (Velsipity) works by sequestering lymphocytes to achieve mucosal healing in moderate-to-severe Ulcerative Colitis. Explore its mechanism, efficacy, and future in Crohn's Disease.
